Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Novo Nordisk ( (NVO) ) has shared an announcement.
Novo Nordisk, the Danish healthcare group specializing in treatments for serious chronic diseases such as diabetes, reported insider-related share transactions involving persons closely associated with its chief financial officer. The disclosure is made under EU market abuse rules and reflects the company’s continued adherence to regulatory transparency standards for management and related-party dealings.
On 7 May 2026, Caroline Munk Esbjerg and Sofie Munk Esbjerg, both closely associated with executive vice president and CFO Karsten Munk Knudsen, each received 50 Novo Nordisk B shares as gifts in off-market transactions valued at around DKK 14,700 apiece. The transactions, formally announced from Bagsværd on 12 May 2026, do not alter control at the company but provide investors added visibility into equity holdings linked to senior management.
The most recent analyst rating on (NVO) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.
The score is driven primarily by strong underlying profitability and multi-year growth (financial performance), supported by very attractive valuation (low P/E and high dividend). Offsetting these positives are weaker recent free-cash-flow conversion and higher leverage, plus a cautious 2026 outlook calling for declining sales and operating profit; technically, momentum is positive but appears overbought and still below the 200-day trend.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with a core focus on defeating serious chronic diseases rooted in its long-standing expertise in diabetes. The group pioneers scientific breakthroughs, works to expand access to its medicines, and aims to prevent and ultimately cure disease, employing about 67,900 people in 80 countries and marketing products in roughly 170 countries.
Average Trading Volume: 20,516,624
Technical Sentiment Signal: Sell
Current Market Cap: $207.1B
Find detailed analytics on NVO stock on TipRanks’ Stock Analysis page.